E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
1. To evaluate the safety and tolerability of PRX302 when used to selectively target and focally ablate histologically proven, clinically significant localised low to intermediate prostate cancer that is associated with an MRI lesion.
|
|
E.2.2 | Secondary objectives of the trial |
2. To evaluate the potential efficacy of PRX302 to selectively target and focally ablate histologically proven, clinically significant, localised low to intermediate prostate cancer that is associated with an MRI lesion, as assessed by biopsy (histological), imaging (MRI) and PSA outcomes. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Men aged ≥40 years and life expectancy of ≥10 years. 2. Serum prostate specific antigen (PSA) ≤15ng/mL. 3. In the planned treatment zone, histologically proven prostate cancer of maximum Gleason Score 7 (3+4 or 4+3) • In the presence of Gleason sum of 7, the maximum cancer core length must be 10mm or less • In the presence of Gleason sum of 7 there is no minimum cancer core length involvement • In the presence of Gleason patterns 3+3 the minimum cancer core length must exceed 3mm. 4. Radiological stage T1-T2 N0 Mx/M0 disease. 5. A visible lesion on mpMRI that is accessible to PRX302 transperineal injection. mpMRI to be obtained at the screening visit or within 3 months prior to dosing. 6. Transperineal prostate biopsy (template mapping and/or targeted) within 12 months prior to dosing, with a clinically significant lesion correlating with an mpMRI visible lesion. 7. Written informed consent by the patient for participation in the study. 8. Patient has an understanding of the English language sufficient to understand written and verbal information about the study and consent process.
|
|
E.4 | Principal exclusion criteria |
1. Previous radiation therapy to the pelvis. 2. Androgen suppression or anti-androgen therapy within the 12 months prior to dosing, for prostate cancer. 3. Use of a 5-alpha reductase inhibitor within the 3 months prior to dosing. 4. Evidence of metastatic disease or nodal disease outside the prostate on bone scan or cross-sectional imaging. 5. Presence of Gleason score >7 and/or maximum cancer core length involvement of >3mm outside of the planned treatment zone. 6. A tumour within the prostate not visible on mpMRI. 7. Inability to tolerate a transrectal ultrasound (TRUS). 8. Known allergy to latex or gadolinium (Gd). 9. Prior rectal surgery preventing insertion of the TRUS probe. 10. Previous electroporation, radiofrequency ablation, high-intensity focused ultrasound (HIFU), cryosurgery, thermal or microwave therapy to treat cancer of the prostate. 11. Transurethral resection of the prostate (TURP) for symptomatic lower urinary tract symptoms within the 6 months prior to dosing. 12. Not fit for major surgery as assessed by a Consultant Anaesthetist. 13. Unable to have pelvic MRI scanning (severe claustrophobia, permanent cardiac pacemaker, metallic implant, etc. likely to contribute significant artefact to images). 14. Presence of metal implants/stents in the urethra or any other non-MRI compatible metal objects. 15. Renal impairment with an estimated glomerular filtration rate (GFR) of <35mL/min (unable to tolerate Gd dynamic contrast enhanced MRI). 16. Use of ANY of the following medications: • Anticoagulants (e.g., Coumadin, heparin) or platelet inhibitors (e.g., aspirin, nonsteroidal anti-inflammatory drugs [NSAIDs], clopidogrel [e.g., Plavix®]) within 5 days prior to dosing or anticipated for use any time within the first 3 days after dosing or per local guidelines. • Androgen deprivation therapy will not be permitted during study duration unless the development of metastases (rare) occurred during study follow-up. 5-alpha reductase inhibitors will not be permitted during the study until the post-treatment biopsies have been taken. 17. Any condition that may confound the assessment of safety and tolerability, such as current symptomatic prostatitis; acute or chronic or symptomatic genitourinary infection; or urinary retention requiring catheterisation within 12 months prior to dosing or elevated International Normalized Ratio (INR) > 1.5 at the time of dosing. 18. Any acute or chronic medical condition that, in the opinion of the Investigator, increases the risk to the patient or the likelihood that the patient will be unable to complete the 30-week study. 19. Unable or unwilling to comply with the requirements of the protocol. 20. Participation in any investigational study within 30 days prior to dosing. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The safety and tolerability of PRX302 will be assessed by recording adverse events, concomitant medications, physicial examinations, baseline medical conditions, vital signs, clinical laboratory tests, urinalysis, PSA, changes in the IIEF, IPSS, UCLA-EPIC Urinary domain and FACT-P.
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Safety will be monitored throughout the study with assessments carried out at Screening and Visit 1 through Visit 7.
|
|
E.5.2 | Secondary end point(s) |
The efficacy of PRX302 will be assessed by biopsy (histological), imaging (MRI) and PSA outcomes. Although the primary objective is to assess safety and tolerability, the key efficacy variable of interest is the successful ablation of the targeted area, defined as the absence of clinically significant prostate cancer in the targeted area as determined by a transperineal targeted biopsy performed 24 weeks post treatment. Other efficacy evaulations will include, proportion of men with the absence of MRI visible disease, proportion of men with a reduction in the size of MRI visible lesion and pilot data on the ability of MRI to predict presence of residual/recurrent clinically significant prostate cancer on biopsy.
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
MRI will be conducted at 2, 12 and 24 weeks. PSA testing will be conducted at Screening, 12 and 24 weeks and Transperineal biopsy will be undertaken at 24 weeks. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | 18 |
E.8.9.1 | In the Member State concerned days | 0 |